Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Compugen Ltd CGEN

Healthcare Biotechnology
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company... see more

Recent & Breaking News (NDAQ:CGEN)

Steven Holtzman Joins Compugen as Strategic Business Advisor

PR Newswire May 10, 2016

Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET

PR Newswire April 27, 2016

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration With Bayer

PR Newswire April 18, 2016

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

PR Newswire April 6, 2016

Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston

PR Newswire March 28, 2016

Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program

PR Newswire February 29, 2016

Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results

PR Newswire February 9, 2016

Compugen Fourth Quarter and Yearend 2015 Conference Call Scheduled for Tuesday, February 9, 2016 at 10:00 AM EST

PR Newswire January 26, 2016

Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Business Wire December 11, 2015

Compugen to Present at the Oppenheimer Healthcare Conference in New York

Business Wire November 24, 2015

Compugen to Present at Jefferies 2015 Global Healthcare Conference in London

Business Wire November 12, 2015

Compugen Presents Translational Study Results Supporting CGEN-15001 for the Treatment of Rheumatoid Arthritis

Business Wire November 9, 2015

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Business Wire November 3, 2015

Compugen Third Quarter 2015 Conference Call Scheduled for Tuesday, November 3, 2015 at 10:00 AM ET

Business Wire October 27, 2015

Compugen Discloses Antibody Drug Conjugate Program Results at the World ADC Summit in San Diego

Business Wire October 19, 2015

Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer

Business Wire September 16, 2015

Compugen to Present at Upcoming Immuno-Oncology and Rheumatology Conferences

Business Wire September 9, 2015

Compugen Ltd. Reports 2nd Quarter 2015 Financial Results

Business Wire August 4, 2015

Compugen Second Quarter 2015 Conference Call Scheduled for Tuesday, August 4, 2015 at 10:00 AM ET

Business Wire July 27, 2015

Compugen to Present at JMP Securities Life Sciences Conference in New York

Business Wire June 15, 2015